John Tilton - Net Worth and Insider Trading

John Tilton Net Worth

The estimated net worth of John Tilton is at least $10,842 dollars as of 2024-04-19. John Tilton is the Chief Commercial Officer of Biohaven Pharmaceutical Holding Co Ltd and owns about 770 shares of Biohaven Pharmaceutical Holding Co Ltd (BHVN) stock worth over $10,842. Details can be seen in John Tilton's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that John Tilton has not made any transactions after 2020-06-10 and currently still holds the listed stock(s).

Transaction Summary of John Tilton

To

John Tilton Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, John Tilton owns 1 companies in total, including Biohaven Pharmaceutical Holding Co Ltd (BHVN) .

Click here to see the complete history of John Tilton’s form 4 insider trades.

Insider Ownership Summary of John Tilton

Ticker Comapny Transaction Date Type of Owner
BHVN Biohaven Pharmaceutical Holding Co Ltd 2020-06-10 Chief Commercial Officer

John Tilton Latest Holdings Summary

John Tilton currently owns a total of 1 stock. John Tilton owns 770 shares of Biohaven Pharmaceutical Holding Co Ltd (BHVN) as of June 10, 2020, with a value of $10,842.

Latest Holdings of John Tilton

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
BHVN Biohaven Pharmaceutical Holding Co Ltd 2020-06-10 770 14.08 10,842

Holding Weightings of John Tilton


John Tilton Form 4 Trading Tracker

According to the SEC Form 4 filings, John Tilton has made a total of 1 transactions in Biohaven Pharmaceutical Holding Co Ltd (BHVN) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Biohaven Pharmaceutical Holding Co Ltd is the sale of 52,000 shares on June 10, 2020, which brought John Tilton around $4 Million.

Insider Trading History of John Tilton

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

John Tilton Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

John Tilton Ownership Network

Ownership Network List of John Tilton

No Data

Ownership Network Relation of John Tilton


John Tilton Owned Company Details

What does Biohaven Pharmaceutical Holding Co Ltd do?

Who are the key executives at Biohaven Pharmaceutical Holding Co Ltd?

John Tilton is the Chief Commercial Officer of Biohaven Pharmaceutical Holding Co Ltd. Other key executives at Biohaven Pharmaceutical Holding Co Ltd include VP & Chief Accounting Officer George C. Clark , Chief Medical Officer Elyse Stock , and Chief Financial Officer James Engelhart .

Biohaven Pharmaceutical Holding Co Ltd (BHVN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Biohaven Pharmaceutical Holding Co Ltd (BHVN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Biohaven Pharmaceutical Holding Co Ltd (BHVN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Biohaven Pharmaceutical Holding Co Ltd (BHVN)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Biohaven Pharmaceutical Holding Co Ltd Insider Transactions

No Available Data

John Tilton Mailing Address

Above is the net worth, insider trading, and ownership report for John Tilton. You might contact John Tilton via mailing address: C/o Biohaven Pharmaceutical Holding Comp 234 Church Street New Haven Ct 06510.

Discussions on John Tilton

No discussions yet.